Rebastinib (DCC-2036)
Rebastinib (DCC-2036)
ChemLeader
Catalog No:
CAS No.:
MDLNo:
Formula:
MW:
Size
5 mg 10 mg 25 mg
Product Availability
3-5days
Price
$155.00
Member price
Product Availability
3-5days
Price
$250.00
Member price
Product Availability
3-5days
Price
$450.00
Member price
Quantity
- +
Product Overview
Product Name Rebastinib (DCC-2036)
CAS1020172-07-9
FormulaC30H28FN7O3
MW553.59
AppearanceWhite to off-white powder
Storage conditionDry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
Security information
Product details

Rebastinib (formerly also known as DCC-2036), a novel, potent and orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity, is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50s of 0.8 nM and 4 nM. It also inhibits other kinases such as SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and has low activity towards c-Kit. DCC-2036 inhibits ABL1 through forcing the kinase domains into inhibitor-bound, inactive Type II conformations. In cellular assay, DCC-2036 inhibits the proliferation of Ba/F3 and K562 cells with IC50 values of 5.4nM and 5.5nM, respectively.

Related literature
Related
Sorry, no related items
History
Rebastinib (DCC-2036)
Tigecycline | GAR-936
(S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6-en-7-yl)methyl)piperazin-1-yl)benzamide